drugset / Trial / NCT00082966
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Phase II trial to study the effectiveness of bortezomib in treating patients who have relapsed or refractory Hodgkin's lymphoma. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth.
Timeline
- Start
- 2004-03
- Primary completion
- 2007-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | Intravenous |
| Background | 17-N-allylamino-17-demethoxygeldanamycin | Unknown | — | Intravenous |